1. Home
  2. ESE vs ERAS Comparison

ESE vs ERAS Comparison

Compare ESE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ESCO Technologies Inc.

ESE

ESCO Technologies Inc.

HOLD

Current Price

$309.68

Market Cap

5.2B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$17.07

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESE
ERAS
Founded
1990
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
5.5B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
ESE
ERAS
Price
$309.68
$17.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
12
Target Price
$283.33
$12.08
AVG Volume (30 Days)
287.0K
4.8M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
0.10%
N/A
EPS Growth
193.15
36.23
EPS
1.11
N/A
Revenue
$37,000,000.00
N/A
Revenue This Year
$21.51
N/A
Revenue Next Year
$6.91
N/A
P/E Ratio
$279.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$145.09
$1.06
52 Week High
$315.19
$18.20

Technical Indicators

Market Signals
Indicator
ESE
ERAS
Relative Strength Index (RSI) 69.29 62.62
Support Level $198.85 $1.57
Resistance Level N/A N/A
Average True Range (ATR) 10.71 1.03
MACD 2.96 0.07
Stochastic Oscillator 88.99 73.62

Price Performance

Historical Comparison
ESE
ERAS

About ESE ESCO Technologies Inc.

ESCO Technologies Inc sells engineered products and systems for utility, industrial, aerospace, and commercial applications. The firm operates in three segments: Aerospace & Defense (A&D), Utility Solutions Group (USG), and RF Test & Measurement (Test). The Aerospace and Defense segment designs and manufactures specialty filtration and naval products. The USG segment provides diagnostic testing solutions. The Test segment provides its customers with the ability to identify, measure, and contain magnetic, electromagnetic, and acoustic energy.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: